Germline and tumor
BRCA1/2, somatic mutation
High grade serous ovarian cancer (HGSOC)
large genomic rearrangement (LRG)
Journal
Annals of translational medicine
ISSN: 2305-5839
Titre abrégé: Ann Transl Med
Pays: China
ID NLM: 101617978
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
entrez:
14
4
2021
pubmed:
15
4
2021
medline:
15
4
2021
Statut:
ppublish
Résumé
Studies on the prevalence of Paired blood and tumor DNA from an unselected cohort of 115 Chinese high grade serous ovarian cancer (HGSOC) patients were collected and analyzed for A total of 115 HGSOC patients were screened. Among them, 30 (26.1%) had germline There is a high germline and tumor
Sections du résumé
BACKGROUND
BACKGROUND
Studies on the prevalence of
METHODS
METHODS
Paired blood and tumor DNA from an unselected cohort of 115 Chinese high grade serous ovarian cancer (HGSOC) patients were collected and analyzed for
RESULTS
RESULTS
A total of 115 HGSOC patients were screened. Among them, 30 (26.1%) had germline
CONCLUSIONS
CONCLUSIONS
There is a high germline and tumor
Identifiants
pubmed: 33850850
doi: 10.21037/atm-20-6827
pii: atm-09-06-453
pmc: PMC8039691
doi:
Types de publication
Journal Article
Langues
eng
Pagination
453Informations de copyright
2021 Annals of Translational Medicine. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm-20-6827). The authors have no conflicts of interest to declare.
Références
Cancer Manag Res. 2019 Jul 08;11:6275-6284
pubmed: 31372034
J Clin Oncol. 2012 Jul 20;30(21):2654-63
pubmed: 22711857
Lancet. 2017 Oct 28;390(10106):1949-1961
pubmed: 28916367
CA Cancer J Clin. 2018 Jul;68(4):284-296
pubmed: 29809280
Diagnostics (Basel). 2019 May 18;9(2):
pubmed: 31109041
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Mol Genet Genomic Med. 2015 Sep;3(5):459-66
pubmed: 26436112
JAMA Oncol. 2016 Apr;2(4):482-90
pubmed: 26720728
J Ovarian Res. 2019 Aug 31;12(1):80
pubmed: 31472684
Gynecol Oncol. 2016 Nov;143(2):379-388
pubmed: 27614696
Diagnostics (Basel). 2019 Aug 01;9(3):
pubmed: 31374917
Lancet Oncol. 2014 Jul;15(8):852-61
pubmed: 24882434
Science. 2003 Oct 24;302(5645):643-6
pubmed: 14576434
Int J Gynecol Cancer. 2019 Jul;29(6):1043-1049
pubmed: 31263023
Front Oncol. 2020 Mar 10;10:295
pubmed: 32211327
Trends Mol Med. 2002 Dec;8(12):571-6
pubmed: 12470990
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
J Gynecol Oncol. 2017 Sep;28(5):e61
pubmed: 28657222
Gynecol Oncol Rep. 2019 Aug 13;29:102-105
pubmed: 31467961
Oncotarget. 2017 Nov 28;8(68):112258-112267
pubmed: 29348823
Int J Gynecol Cancer. 2017 Oct;27(8):1650-1657
pubmed: 28692638
Clin Cancer Res. 2014 Feb 1;20(3):764-75
pubmed: 24240112
Nat Rev Cancer. 2015 Nov;15(11):668-79
pubmed: 26493647
J Transl Med. 2016 Sep 15;14:267
pubmed: 27634150
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
BMC Cancer. 2019 Jun 28;19(1):641
pubmed: 31253107
Clin Cancer Res. 2015 Feb 1;21(3):652-7
pubmed: 25398451
Cancer. 2005 Dec 15;104(12):2807-16
pubmed: 16284991
J Pers Med. 2020 May 21;10(2):
pubmed: 32455595